Introduction 2-Arylpropionic acids (profen drugs) are a widely used class of nonsteroidal antiinflammatory drugs (NSAIDs), which have a chiral center at the carbon alpha to the carboxyl group. They are dosed therapeutically as racemic mixtures, with the notable exception of naproxen. In vitro studies suggested that anti-inflammatory activity resides almost exclusively in the (S)-enantiomer (Williams, 1990 ). Yet, the two enantiomers of profen drugs have been shown to exhibit similar anti-inflammatory properties in vivo, since the inactive (R)-enantiomers are unidirectionally inverted in vivo to the active (S)-enantiomers (Hutt and Caldwell, 1983; Caldwell et al., 1988) . The mechanism of this inversion is believed to involve the enantioselective formation of acyl-coenzyme A (acylCoA) thioester followed by enzymatic epimerization and hydrolysis to regenerate free acids ( Fig. 1) (Nakamura et al., 1981; Hall and Quan, 1994) . Enantioselective activation of the (R)-enantiomers to their acyl-CoA thioesters is believed to be the key step in such chiral inversion, because it accounts for the apparent unidirectional nature of the process (R to S, but not vice versa) in humans and several animal species (Caldwell et al., 1988) .
The activated acyl-CoA derivatives of profen drugs also serve as obligatory intermediates for the formation of amino acid conjugates, acyl carnitine derivatives, as well as hybrid triacylglycerides (Fears, 1985; Hutt and Caldwell, 1990) (Fig. 1) . Because of the electrophilic nature of the thioester bond, acyl-CoA thioesters of a number of xenobiotic carboxylic acids, including nafenopin (Sallustio et al., 2000) , clofibric acid (Grillo and Benet, 2002) , 2-phenylpropionoic acid (2-PPA) (Li et al., 2002b) , naproxen (Olsen et al., 2002) , 2,4-dichlorophenoxyacetic acid (Li et al., 2003a) , tolmetin (Olsen et al., 2003 and 2007) and zomepirac (Olsen et al., 2005) , have been demonstrated to be This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 10, 2008 as DOI: 10.1124 at ASPET Journals on June 13, 2017 dmd.aspetjournals.org Downloaded from chemically reactive and capable of acylating biological nucleophiles, such as glutathione (GSH) and proteins. Studies with 8 structurally diverse carboxylic acids showed that, like acyl glucuronides (Benet et al., 1993) , the chemical reactivity of acyl CoA thioesters depends on the electronic nature and degree of substitution at the α-carbon and thus could be predicted from their chemical structures (Sidenius et al., 2004) .
Most profens are metabolized to acyl glucuronides and acyl-CoA thioesters, both of which have been demonstrated to be chemically reactive and are believed to mediate covalent adduct formation in vivo ( Fig. 1 ) (Li and Benet, 2002; Boelsterli, 2002) .
Comparative in vitro studies with several carboxylic acids, including clofibric acid (Grillo and Benet, 2001; Shore et al., 1995) , 2-PPA (Li et al., 2002b) and naproxen (Olsen et al., 2002) , showed that acyl-CoA thioesters are 40-70 fold more reactive toward GSH, forming acyl glutathione conjugates, than the respective acyl glucuronides in vitro in buffer. In the case of 2-PPA, metabolic activation by acyl-CoA formation has been shown to contribute more to covalent binding than the corresponding acyl glucuronidation in vitro in hepatocytes (Li et al., 2002a) and in vivo in rats (Li et al., 2003b) .
Considering the potential importance of acyl-CoA thioesters in covalent binding, we hypothesized that the extent of covalent adduct formation of profen drugs might be modulated by agents that regulate acyl-CoA formation. Our previous studies showed that the extent of covalent binding of 2-PPA to hepatic protein was markedly decreased when the corresponding acyl-CoA formation was inhibited by trimethylacetic acid (Li et al., 2003b) . It is unknown, however, whether the agents that potentially upregulate acyl-CoA pathways could enhance the extent of covalent binding. (Rader and Haffner, 1999) . Administration of these fibrates is known to induce several hepatic enzymes associated with fatty acid metabolism, including acyl-CoA synthetases, the enzymes that catalyze the formation of acyl-CoA thioesters (Alegret et al., 1994; Schoonjans et al., 1993) . A significant increase of free CoA, a cofactor that is essential for acyl-CoA formation, was observed in the livers of rats treated with fibrates (Horie et al., 1986) . In addition, Shirley et al. (1994) have reported that ibuprofen-CoA formation was significantly higher in hepatocytes from clofibric acid-treated rats than the corresponding controls. Based on these data, we used 2-PPA as a model compound to evaluate the effect of fibrates on the two alternative metabolic activation pathways of profens, namely acyl-CoA formation and acyl glucuronidation, and ultimately on the extent of covalent binding of 2-PPA to liver protein. Among the three fibrates examined in the present studies, clofibric acid is the pharmacological active form of clofibrate, the first and most extensively studied fibrate, whereas fenofibrate and gemfibrozil are the only two fibrates that are currently prescribed in the U.S. This article has not been copyedited and formatted. The final version may differ from this version. 7.8, i.p.), 260 mg/kg/day fenofibrate prepared in 0.5% methylcelullose (oral gavage), or 180 mg/kg/day gemfibrozil in 0.5% methylcellulose (oral gavage) for 7 days. The doses of these three fibrates were chosen in such a way as to be approximately equivalent to each other (~0.7 mmol/kg/day) and also within the dose range commonly used in fibrate induction studies (Bremer et al., 1981; Schoonjans et al., 1993; . Alegret et al. (1994) showed that maximal induction of palmitoyl-CoA synthetase was achieved after 7-day fibrate treatment, and thus, 7-day treatment was used in the present study. An additional 10 rats, 5 for each treatment, received the corresponding dosing vehicles, namely 0.1 M sodium bicarbonate (pH 7.8, i.p.) or 0.5% methylcellulose (oral gavage). Data analysis showed that there were no significant differences in the percentage of increase in body weight, liver weight and activities of acyl-CoA synthetases between the two vehicle treatments. Consequently, the data from these two vehicle treatments were combined and reported as one group.
On Day 8, the rats were anesthetized with ether, the abdominal cavities opened and the livers perfused with ice-cold saline. Perfused livers were rapidly removed, weighed and frozen immediately in liquid nitrogen. Rat liver homogenate was prepared as described previously (Li et al., 2003c) . To determine (R)-2-PPA-CoA synthetase activity, (R)-2-PPA (1 mM) was incubated with 0.25 mg liver homogenate protein, 0.05% Triton X-100, 1 mM DTT, 2 mM EDTA, 1.2 mM CoA, 6.2 mM MgCl 2 and 2.5 mM ATP in a final volume of 0.5 mL (Li et al., 2003c) . After a 3 min preincubation, reactions were In vivo studies with 2-PPA. Clofibric acid was administered i.p. as a sodium bicarbonate solution, whereas fenofibrate and gemfibrozil were dosed as suspension in 0.5% methylcellulose via oral gavage due to the apparent insolubility of fenofibrate and gemfibrozil in buffer. No attempt was made to re-evaluate clofibric acid in 0.5% methylcellulose via oral gavage, since clofibric acid was reported to be completely absorbed orally in rats (Cayen et al., 1977) and there was no significant difference in the in vitro and in vivo observations between the two control groups, namely sodium bicarbonate-treated (i.p.) and 0.5%-methylcellulose-treated (oral gavage) groups.
This article has not been copyedited and formatted. The final version may differ from this version. carried out as described previously (Li et al., 2003b) . Quantitative measurements of 2-PPA-CoA and 2-PPA acyl glucuronide were made using a standard curve generated from absolute peak areas, by spiking liver samples of untreated rats with synthetic 2-PPA-CoA and biosynthetic 2-PPA acyl glucuronide standards, followed by processing as described above.
Statistical Analysis. Data were analyzed by unpaired Student's t test when there were only two treatment groups. ANOVA was utilized when the treatment groups are equal to or more than 3. In this case, when significant differences were found, pairwise multiple comparisons were conducted using the Student-Newman-Keuls method with significance set at p < 0.05.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
All the animals showed a steady increase in body weight during the 7-day treatment. Except for fenofibrate-treated rats, there were no significant differences in the percentage increase in body weight after 7-day treatment with gemfibrozil, clofibric acid and control vehicles (Table 1) . Rats treated with fenofibrate for 7 days exhibited significantly less percentage body weight gain as compared with the other three groups (P < 0.05) ( Table 1 ). In contrast, there was a significant increase in liver weight in fibrate-treated animals (31%, 24% and 51% increase in gemfibrozil-, clofibric acid-and fenofibrate-treated animals, respectively, as compared to controls, p <0.05) ( Table 1 ).
These observations were in agreement with the typical hepatomegaly of fibrates observed previously (Hawkins et al., 1987; Skrede and Halvorsen, 1979) .
Studies with rat liver homogenate showed that treatment with the three fibrates led to significant increases (1.3-2.6 fold) in long-chain acyl-CoA synthetase activity (measured by palmitoyl-CoA formation) (Table 1) , consistent with the previous mRNA (Schoonjans et al., 1993) and protein (Scheuerer et al., 1998) findings. Marked increases (4-8 fold) of (R)-2-PPA-CoA formation were also observed in liver homogenates treated with these fibrates (Table 1) . On an equimolar basis, clofibric acid appeared to exhibit greater inductive effects on these two enzyme activities than gemfibrozil, and less effects than fenofibrate.
In agreement with the increased 2-PPA-CoA formation in rat liver homogenate, clofibric acid-treated rats exhibited much higher levels of hepatic 2-PPA-CoA thioester than controls over a 2 h period ( Fig. 2A and Table 2 period was markedly increased by 2.9 fold by clofibric acid ( Fig. 2A and Table 2 ). The fold increases observed in vivo, however, were much less than that observed in vitro in liver homogenate (6.8 fold increase in 2-PPA-CoA formation as compared to controls) (Table 1) . Clofibric acid-treatment did not significantly change the hepatic concentrationtime profile of 2-PPA and its corresponding acyl glucuronide as compared to controls ( Fig. 2 B and C, and Table 2 ).
The effects of clofibric acid on the metabolic activation of 2-PPA and the extent of covalent binding of 2-PPA to liver protein were further examined 2 h post (R,S)-[1-
14 C]-2-PPA administration. As shown in Table 2 , the hepatic levels of 2-PPA-CoA and acyl glucuronide 2 h post-administration of (R,S)-[1-14 C]-2-PPA were consistent with those levels 2 h after non-radiolabeled (R,S)-2-PPA treatment (Fig. 2) . Due to the limited availability of (R,S)-[1-14 C]-2-PPA in our laboratory, time-dependent studies with (R,S)- Table 2 , treatment with clofibric acid, which markedly increased the hepatic exposure of 2-PPA-CoA by 2.9 fold, significantly increased covalent binding to hepatic protein by 25% (p < 0.05) 2 h post administration
In contrast to clofibric acid, treatment with fenofibrate did not significantly change 2-PPA-CoA concentrations in rat livers, whereas gemofibrozil significantly decreased the hepatic levels of 2-PPA-CoA thioester (p <0.05) (Fig. 3A) . decreased by both fenofibrate-and gemfibrozil-treatment, as compared with controls (0.5% methylcellulose-treated) (Fig. 3B ). Both treatments led to significant decreases (25 and 29% decrease in fenofibrate and gemfibrozil-treated rats, respectively, as compared to controls, p < 0.05) in covalent binding of 2-PPA to hepatic protein (Fig. 3C ).
Discussion
The primary goal of the present investigation was to evaluate the inductive effects of fibrates on the two alternative metabolic activation pathways of 2-PPA in vivo in rats.
These studies were undertaken as a first ( Fig. 2A and Table 2 ). In contrast, on an equimolar basis, treatment with fenofibrate appeared to have no effect on 2-PPA-CoA concentrations in rat livers, whereas gemfibrozil treatment led to a significant decrease in the hepatic levels of 2-PPA-CoA thioesters (p <0.05) 2 h post 2-PPA administration (Fig. 3A) . The good reproducibility of these studies suggests that these unexpected observations are unlikely the result of experimental artifacts.
We do not, at this point, understand the mechanism for the apparent discrepancy observed between in vitro and in vivo results among the three fibrates and this will be an area of future investigation. As depicted in Fig. 1 , 2-PPA-CoA thioester is a metabolic intermediate, which not only mediates the chiral inversion of 2-PPA, but also readily undergoes enzyme-mediated hydrolysis, and may readily conjugate with amino acids and carnitine, and incorporate into lipids. Therefore, the hepatic level of 2-PPA-CoA thioester depends not only on the formation of 2-PPA-CoA thioester, but also on its subsequent metabolism. In fact, it has been documented that fibrates also upregulate acyl-CoA hydrolase (Berge and Bakke, 1981; Alegret et al., 1994) and carnitine acyl transferase, the enzyme that catalyzes the formation of acyl-carnitine from acyl-CoA thioester (Tosh et al., 1989) , in addition to their effects on acyl-CoA synthetase. Scheuerer et al. (1998) demonstrated that clofibrate treatment significantly increased the distribution of radiolabeled ibuprofen to several tissues, including liver and fat, and concluded that such , 1986; Bhuiyan et al., 1988; Skrede and Halvorsen, 1979) . The effects of fenofibrate and gemfibrozil treatment on the hepatic content of CoA, however, are still unknown. It is possible that availability of hepatic CoA may limit the formation of 2-PPA-CoA thioester in vivo and thus contribute to the apparent in vitro and in vivo disconnect.
In contrast to 2-PPA-CoA, the three fibrates appeared to exhibit similar effects on the hepatic levels of 2-PPA acyl glucuronide. Treatment with both fenofibrate and gemfibrozil led to significant decreases in the hepatic levels of 2-PPA acyl glucuronide 2 h post 2-PPA administration (Fig. 3B) , whereas clofibric acid also slightly, although not significantly, decreased the hepatic exposure of 2-PPA acyl glucuronide by 21% over the 2-hr period (Fig. 2B ). These observations are consistent with previous reports that clofibrate had no inductive effects on acyl glucuronidation of acidic drugs (FournelGigleux et al., 1988; Ritter, 2000) . In fact, a small reduction of 2-PPA acyl glucuronidation has been reported in vitro in liver microsomes from clofibric acid-treated rats (Fournel-Gigleux et al., 1988) . However, it is possible that the decrease of hepatic levels of 2-PPA acyl glucuronide could also result from increased hepatic excretion of 2-PPA acyl glucuronide, in addition to reduction of formation.
The effects of these three fibrates on the extent of covalent binding of 2-PPA to hepatic protein were different (Table 1 and In conclusion, this is the first study to demonstrate that the three commonly This article has not been copyedited and formatted. The final version may differ from this version. 
